LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies	B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Tumor Virus Infections, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, neoplasm, non-Hodgkin lymphoma, viral infectious disease	Recruiting	Phase 1	2026-08-06		NCT05990465

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Medical College of Wisconsin	201

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Froedtert & the Medical College of Wisconsin	Milwaukee	United States	31